Introduction
============

Numerous researchers have studied the associations between miRNA expression and the survival outcomes of colorectal cancer (CRC) patients.[@b1-cmar-10-907]--[@b258-cmar-10-907] CRC has a 10% cancer incidence and mortality worldwide,[@b259-cmar-10-907] and thus, it is one of the most serious diseases threatening human health. Despite great success in the treatment of CRC, the prognosis of CRC patients is still poor. Therefore, it is fundamental for the diagnosis, treatment, and prognosis of CRC patients to understand its emphasized molecular origin.[@b260-cmar-10-907] Despite a comprehensive study about the mechanisms of CRC, there are still some challenges that require recognizing prognostic biomarkers with minimal invasion and sensitivity. Accordingly, it is of vital significance to improve the survival rate of CRC patients, utilizing rapid and reliable tumor-prognosis biomarkers.

miRNAs, small noncoding RNA gene products of approximately 22 nucleotides, are found in various types of organisms. They account for 2%--5% of the entire genome, number about 1,000, and regulate the expression of ≥20% of human genes.[@b261-cmar-10-907] In addition, they play crucial roles in regulating the translation and degradation of mRNAs via base pairing to partially complementary sites, predominantly in the 3′-untranslated areas of mRNAs.[@b262-cmar-10-907]--[@b264-cmar-10-907]

In the study of CRC, a large number of articles have covered the fact that miRNAs are closely related to the survival time of patients.[@b1-cmar-10-907]--[@b258-cmar-10-907] There were relatively small samples in these papers, and the present work aims to estimate the most accurate prognostic value between miRNA level and survival outcome of CRC patients, better to comprehend the miRNAs with prognostic pertinence that are potential candidates for clinical verification in the future.

Materials and methods
=====================

Search strategy
---------------

We used four online databases -- PubMed, Embase, Web of Science, and the Cochrane Library -- to find pertinent literature published until May 20, 2017. The combination term "miR and colorectal cancer" was employed for the literature search. Two authors (S Gao and ZY Zhao) independently performed this comprehensive online search.

Inclusion criteria
------------------

Articles qualified if they satisfied the following criteria: patients with colon/rectal cancer or CRC; miRNA levels in tissue, plasma, or serum and survival results were measured; at least one survival curve was measured of overall survival (OS), cause-specific survival (CSS), disease-free survival (DFS), recurrence-free survival (RFS), progression-free survival (PFS), and metastasis-free survival (MFS), with or without HRs/95% CIs; and full text published in English.

Exclusion criteria
------------------

Exclusion criteria were experimental studies, reviews, or letters without primary data and retracted papers; frequency of research evaluating prognostic value of miRNAs in tissue of four or less. Only the most comprehensive study was included for this meta-analysis if more than one paper had been published in the same research group.

Quality assessment
------------------

SG and ZY Zhao identified all qualifying studies analyzing the prognostic value of miRNAs in CRC, and YZ reevaluated uncertain data.

Study selection
---------------

A flow diagram of the study selection process is presented in [Figure 1](#f1-cmar-10-907){ref-type="fig"}. Our study found 1,843 articles for consideration within this meta-analysis, and 322 articles suitable for assessment of prognostic miRNA signatures in CRC and full-text papers were acquired by evaluating titles and abstracts. On elaborate review of research methodologies, 64 investigations were excluded, the details of which are shown in [Figure 1](#f1-cmar-10-907){ref-type="fig"}. On the basis of the exclusion criteria, 63 studies were finally included in this meta-analysis.

Study frequency
---------------

The frequency of studies estimating the prognostic value of miRNAs in CRC are shown in [Tables 1](#t1-cmar-10-907){ref-type="table"} (blood) and 2 (tissue), including miRNA name, number of studies estimating prognostic value, and references.

Study characteristics
---------------------

Literature with Kaplan--Meier survival curves for CRC are detailed in [Table 3](#t3-cmar-10-907){ref-type="table"}. If data were not provided visually and merely as curves, they were extracted from the curves, and estimated HRs with 95% CIs were subsequently calculated using the method of Tierney et al[@b265-cmar-10-907] with Engauge Digitizer version 4.1 software. In addition, if outcomes of both univariate and multiple covariates were covered, only the latter was chosen, because of adjustment for confounders.

Statistical analyses
--------------------

All analyses were performed utilizing Stata version 13.0 (StataCorp, College Station, TX, USA). Merged HRs were regarded as significant at the *P*\<0.05 level if 95% CIs did not contain the value 1. Effect values for HRs were regarded as large if ≥2. HRs for OS were regarded as the prime reference standard if OS *P*-values were inconsistent with other survival outcomes with respect to the associated miRNA level. All analyses employed random-effect models instead of fixed-effect models, because there existed differences among the studies, including tissue detected (frozen or formalin-fixed, paraffin-embedded), blood (plasma or serum), tumor stage (I--IV), cutoff values, and miRNA-analysis methods. Publication bias was measured by Begg's funnel plot, and a two-tailed *P*-value \<0.05 was regarded as significant. The trim-and-fill method was performed if publication bias occurred. Sensitivity analysis was employed to weigh how powerful merged HRs were after a single study had been removed. An individual study was suspected of having excess of influence if the point estimation was outside the 95% CI after removal from the analysis.

Results
=======

Meta-analysis
-------------

An overview of HRs appraised from comprehensive analysis of all the miRNAs is given in [Table 4](#t4-cmar-10-907){ref-type="table"}. Thirteen miRNAs were involved in this meta-analysis: miR21, miR92a, miR106a, miR125b, miR126, miR141, miR143, miR145, miR181a, miR200b, miR203, miR224, and miR429. Results of survival analyses of these miRNAs are given in [Figures 2](#f2-cmar-10-907){ref-type="fig"}[](#f3-cmar-10-907){ref-type="fig"}[](#f4-cmar-10-907){ref-type="fig"}[](#f5-cmar-10-907){ref-type="fig"}[](#f6-cmar-10-907){ref-type="fig"}[](#f7-cmar-10-907){ref-type="fig"}--[8](#f8-cmar-10-907){ref-type="fig"}.

CRC patients with high blood miR141, high tissue miR181a and miR224, or low tissue miR126 expression have significantly shorter OS
----------------------------------------------------------------------------------------------------------------------------------

Two studies[@b14-cmar-10-907],[@b19-cmar-10-907] focused on associations between high blood miR141 levels and OS, indicating that CRC patients with high blood miR141 levels had significantly shorter OS than those with low miR141 expression (HR 2.52, 95% CI 1.68--3.77, *P*\<0.01; [Figure 2](#f2-cmar-10-907){ref-type="fig"}). Five papers[@b120-cmar-10-907],[@b122-cmar-10-907]--[@b125-cmar-10-907] stressed connections between low tissue miR126 levels and OS, suggesting that CRC patients with low expression of tissue miR126 levels had significantly poorer OS than those with high miR126 expression (HR 1.55, 95% CI 1.24--1.93, *P*\<0.01; [Figure 6](#f6-cmar-10-907){ref-type="fig"}).

Three articles concentrated on the relationship between high tissue miR181a levels and OS, demonstrating that CRC patients with high miR181a levels had significantly worse OS than those with low miR181a expression (HR 1.52, 95% CI 1.26--1.83, *P*\<0.01; [Figure 7](#f7-cmar-10-907){ref-type="fig"}). Four studies paid attention to correlations between high expression of tissue miR224 levels and OS, showing that CRC patients with high tissue miR224 levels had significantly shorter OS than those with low miR224 expression (HR 2.12, 95% CI 1.04--4.34, *P*=0.04; [Figure 8](#f8-cmar-10-907){ref-type="fig"}).

There was no significant relationship between high expression levels of blood miR21, miR92a, miR200b, miR203, tissue miR106a, miR125b, or miR429 or low expression levels of tissue miR143 or miR145 and OS
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Details are given in [Table 4](#t4-cmar-10-907){ref-type="table"} and [Figures 2](#f2-cmar-10-907){ref-type="fig"} and [5](#f5-cmar-10-907){ref-type="fig"}[](#f6-cmar-10-907){ref-type="fig"}[](#f7-cmar-10-907){ref-type="fig"}--[8](#f8-cmar-10-907){ref-type="fig"}.

High tissue miR21 expression forecasts poor OS
----------------------------------------------

Thirteen investigations[@b5-cmar-10-907],[@b60-cmar-10-907]--[@b68-cmar-10-907],[@b70-cmar-10-907]--[@b73-cmar-10-907] analyzed the connection between high tissue miR21 levels and OS, showing that CRC patients with high tissue miR21 levels had significantly worse OS than those with low miR21 expression (HR 1.31, 95% CI 1.12--1.53, *P*\<0.01; [Figure 3A](#f3-cmar-10-907){ref-type="fig"}).

Publication bias
----------------

To assess publications showing some degree of bias for OS of CRC patients with high tissue miR21 levels, our study used Begg's funnel plot ([Figure 3B](#f3-cmar-10-907){ref-type="fig"}). The *P*-value was less than 0.01, indicating the presence of publication bias. As such, the trim-and-fill method was performed and the pooled HR recalculated with presumed missing studies to estimate asymmetry in the funnel plot ([Figure 4A](#f4-cmar-10-907){ref-type="fig"}), indicating no publication bias (*P*=0.73). The recalculated HR changed significance for OS (HR 1.13, 95% CI 0.96--1.34, *P*=0.15; [Figure 4B](#f4-cmar-10-907){ref-type="fig"}).

Sensitivity analysis
--------------------

For research on OS of CRC patients with high tissue miR21 levels, the sensitivity analysis did not manifest alterations during outcomes on the basis of the exclusion of any single investigation ([Figure 3C](#f3-cmar-10-907){ref-type="fig"}), showing that no sole study significantly affected the merged HR or 95% CI. This also proved true for the outcome of OS adjusted with the trim-and-fill method ([Figure 4C](#f4-cmar-10-907){ref-type="fig"}).

Key findings
------------

We carried out a meta-analysis of 13 miRNAs and OS. Serving as the most investigated miRNA, miR21 (high tissue levels) in CRC showed significantly shorter OS than low tissue miR21 levels (*P*\<0.05). However, there was no significant relationship between high blood miR21 levels and OS (*P*=0.47). The different detected sample types and relatively small sample capacity of the miR21 blood group (only three studies analyzing the relationship between blood miR21 levels and OS) may have been potential clinical reasons and caused the statistical significance between tissue and blood miR21 levels.

Encouragingly, the HR from analysis of the association between high tissue miR21 levels and OS (multiple-covariate analysis)[@b5-cmar-10-907],[@b60-cmar-10-907],[@b63-cmar-10-907],[@b65-cmar-10-907],[@b66-cmar-10-907],[@b68-cmar-10-907],[@b71-cmar-10-907],[@b73-cmar-10-907] was 1.47, which was greater than that reported in any of the 13 articles.[@b5-cmar-10-907],[@b60-cmar-10-907]--[@b78-cmar-10-907],[@b70-cmar-10-907]--[@b73-cmar-10-907] Nevertheless, the significance did not remain in accordance with the forest plot, which was adjusted with the trim-and-fill method because publication bias existed (*P*\<0.01; [Figure 3B](#f3-cmar-10-907){ref-type="fig"}). This result indicated that the prognostic value of tissue miR21 was not stable in CRC patients. There were other miRNAs with significant prognostic value in CRC, including blood miR141 and tissue miR21, miR181a, miR224, and miR126 (*P*\<0.05). Among these, blood miR141 and tissue miR224 were powerful prognostic candidates in CRC (HR ≥2).

Discussion
==========

Present situation
-----------------

Increasing numbers of studies have indicated that diverse miRNAs are connected with survival results in CRC patients.[@b1-cmar-10-907]--[@b258-cmar-10-907] Nevertheless, no systematic review or meta-analysis has evaluated HRs between miRNA levels and survival outcomes of CRC patients. Therefore, it was of vital significance to launch a meta-analysis to comprehend the relationship between expression levels of miRNAs and prognoses of CRC patients.

Molecular mechanisms for miRNAs researched
------------------------------------------

An overview of miRNAs with dysregulated expression and their potential targets and pathways of entry is detailed in [Figure 9](#f9-cmar-10-907){ref-type="fig"}. There was noticeable functional overlap and relationships among the miRNAs. Seven miRNAs (miR21, miR106a, miR126, miR143, miR181a, miR224, and miR429) touched upon cell functions, including cell apoptosis, cell cycle, and death. To sum up, these associations may refer to CRC progression.

Other CRC molecular pathways
----------------------------

In addition to miRNAs, there are some other molecular data that can be confounders, related to mortalities, such as the chromosomal instability pathway, the DNA mismatch repair system, and microsatellite instability (MSI). Features of distinctive pathways are different models of genetic instability, succeeding clinical presentations, and features of pathological behavior. A majority of CRC follows the chromosomal instability pathway, features of which are extensive loss of heterozygosis and gross chromosomal abnormalities.[@b266-cmar-10-907],[@b267-cmar-10-907] Second, about 15% of CRC is due to the derangement of the DNA mismatch repair system and consequential MSI. The former is in charge of protein production, which identifies and directly repairs mononucleotide mismatches at MS sequences that escape the proofreading system of DNA polymerase. Furthermore, a previous meta-analysis indicated that MSI-high CRC patients had a 40% better OS rate compared with MS-stable CRC patients.[@b268-cmar-10-907]

Molecular pathological epidemiology (MPE)
-----------------------------------------

MPE is a multidisciplinary research field of associations between endogenous and exogenous ingredients, molecular cancer biomarkers, and cancer progression and also a comprehensive interdisciplinary science on the strength of the characteristic principal and continuum theory of diseases.[@b269-cmar-10-907],[@b270-cmar-10-907] Other than miRNAs, DNA mutation and methylation and other diagnostics, such as blood tests, also play crucial roles in cancer prognosis and MPE, which deeply investigates environmental exposure, intermediate phenotypes, such as blood biomarkers, and molecular changes in cancer using molecular pathologic analyses. MPE helps precision medicine by providing robust evidence for exposure--outcome associations, such as with drugs.

Strengths
---------

This study has some strengths. Almost all the articles with survival consequences in CRC patients with disparate miR-NAs were searched. Furthermore, the current expression profile of miRNAs is explicitly detailed in [Tables 1](#t1-cmar-10-907){ref-type="table"} and [2](#t2-cmar-10-907){ref-type="table"} according to miRNAs and types of detected samples (blood or tissue). Papers assessing at least one of the survival curves of OS, CSS, DFS, RFS, PFS, and MFS were eventually included, and papers covering merely HRs or 95% CIs without any of the survival curves were excluded. Meta-analyses were performed on miRNAs investigated five or more times in CRC tissues. Virtually all the studies included had sample sizes ≥30 (except two),[@b70-cmar-10-907],[@b111-cmar-10-907] reinforcing the usability and enlarging the feasibility of consequences to CRC patients.

Limitations
-----------

Nevertheless, we cannot overemphasize the following limitations. There was much heterogeneity in designs of studies, and most of the outcomes from our meta-analyses contained high heterogeneity (*I*^2^≥50%). Statistical assessment of publication bias was suboptimal. There existed differences among the studies, including tissue-detected (frozen or formalin-fixed, paraffin-embedded), blood (plasma or serum), tumor stage (I--IV), cutoff values, and miRNA methods. The present meta-analysis simply included papers published in English, perhaps excluding potential studies published in other languages with respect to miRNA level and prognosis of CRC patients. Papers covering only HRs or 95% CIs without survival curves were excluded, lowering the sample sizes of the papers included. Because of the massive interrelation between papers and data about CRC, we subjectively and selectively included specific studies on the basis of the inclusion and exclusion criteria, bringing about the omission of several possible miRNAs with prognostic value and a relatively small number of included studies. The studies included contained three types of cancers (colon and rectal cancer and CRC), which blurred the division between tumor types. Some blood miRNAs were from cell-free RNA, while others were from exosome isolates. These were considered the same to some degree and may have caused some deviations in the final results.

Implications for prospective clinical and scientific study
----------------------------------------------------------

It should be mentioned that the current meta-analysis is the first system assessment of the pertinence of miRNA level to the prognosis of CRC patients. This study presents foundations for prospective clinical and scientific study with respect to clinical staff and other health care providers, for whom simultaneous determination of miRNA expression is able greatly to reinforce assessment of life expectancy of CRC patients, thus enabling prompt therapy, and for scientific researchers. Current research progress and trends in connections between miRNAs and prognosis of CRC patients are shown in [Tables 1](#t1-cmar-10-907){ref-type="table"} and [2](#t2-cmar-10-907){ref-type="table"}. Selectively basic experiments can be conducted using these details ([Figure 9](#f9-cmar-10-907){ref-type="fig"}). Conflicting results on the prognosis of miRNAs may be addressed based on the present meta-analysis.

Conclusion
==========

In general, blood miR141 and tissue miR21, miR181a, miR224, and miR126 have significant prognostic value. Among these, blood miR141 and tissue miR224 are strong biomarkers of prognosis in CRC.
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![Flow diagram of literature search and selection.](cmar-10-907Fig1){#f1-cmar-10-907}

![Pooled analyses of OS or DFS in association with high blood miR21-, miR92a-, miR141-, miR200b-, and miR203-expression levels.\
**Note:** Weights are from random-effect analysis.\
**Abbreviations:** OS, overall survival; DFS, disease-free survival.](cmar-10-907Fig2){#f2-cmar-10-907}

![(**A**) Forest plots of pooled analyses of OS or OS (multiple-covariate analysis) in association with high tissue miR21-expression levels; (**B**) Begg's funnel plot of publication bias for pooled analysis of OS in association with high tissue miR21-expression levels; (**C**) sensitivity analysis of pooled analysis of OS in association with high tissue miR21-expression levels; (**D**) forest plots of pooled analyses of DFS or RFS/CSS/MFS/PFS in association with high tissue miR21-expression levels. Weights are from random-effects analysis in A and D. ^a^Multiple-covariate analysis; ^b^univariate analysis.\
**Abbreviations:** OS, overall survival; DFS, disease-free survival; RFS, recurrence-free survival; CSS, cause-specific survival; MFS, metastasis-free survival; PFS, progression-free survival.](cmar-10-907Fig3){#f3-cmar-10-907}

![(**A**) Funnel plot of pooled analysis adjusted with the trim-and-fill method of OS in association with high tissue miR21-expression levels. Circles, included studies; diamonds, presumed missing studies. (**B**) Forest plot of pooled analysis adjusted with the trim-and-fill method of OS in association with high tissue miR21-expression levels. (**C**) Sensitivity analysis of pooled analysis adjusted with the trim-and-fill method of OS in association with high tissue miR21-expression levels. Weights are from random-effects analysis. ^a^Multiple-covariate analysis; ^b^univariate analysis.\
**Abbreviation:** OS, overall survival.](cmar-10-907Fig4){#f4-cmar-10-907}

![Pooled analyses of OS or DFS/MFS in association with high tissue miR106a- and miR125b-expression levels. Weights are from random-effects analysis.\
**Abbreviations:** OS, overall survival; DFS, disease-free survival; MFS, metastasis-free survival; TCGA, the Cancer Genome Atlas.](cmar-10-907Fig5){#f5-cmar-10-907}

![Pooled analyses of OS, PFS/RFS/CSS, or DFS/CSS/PFS in association with low tissue miR126- and miR143-expression levels. Weights are from random-effects analysis.\
**Abbreviations:** OS, overall survival; DCCG, Dutch Colorectal Cancer Group; PFS, progression-free survival; RFS, recurrence-free survival; CSS, cause-specific survival; DFS, disease-free survival.](cmar-10-907Fig6){#f6-cmar-10-907}

![Pooled analyses of OS, MFS/DFS or DFS/CSS/PFS/RFS in association with high tissue miR145-expression levels or low tissue miR181a-expression levels. Weights are from random-effects analysis.\
**Abbreviations:** OS, overall survival; TCGA, the Cancer Genome Atlas; MFS, metastasis-free survival; DFS, disease-free survival; CSS, cause-specific survival; PFS, progression-free survival; RFS, recurrence-free survival.](cmar-10-907Fig7){#f7-cmar-10-907}

![Pooled analyses of OS or DFS/MFS in association with high tissue miR224- and miR429-expression levels. Weights are from random-effects analysis.\
**Abbreviations:** OS, overall survival; TCGA, the Cancer Genome Atlas; DFS, disease-free survival; MFS, metastasis-free survival.](cmar-10-907Fig8){#f8-cmar-10-907}

![Summary of microRNAs with altered expression and potential targets and pathways entered in this study.\
**Abbreviations:** ATG7, autophagy related 7; E2F1, E2F transcription factor 1; TGFBR2, transforming growth factor beta receptor 2; CDKN1A, cyclin dependent kinase inhibitor 1A; TP53, tumor protein p53; BCL2, apoptosis regulator; CXCR4, C-X-C motif chemokine receptor 4; TLR2, toll like receptor 2; PTEN, phosphatase and tensin homolog; WIF1, WNT inhibitory factor 1; CDH1, cadherin 1; PHLPP1, PH domain and leucine rich repeat protein phosphatase 1; PHLPP2, PH domain and leucine rich repeat protein phosphatase 2; MBD2, methyl-CpG binding domain protein 2; SMAD4, SMAD family member 4; SOX2, SRY-box 2; HOXA5, homeobox A5; AKT1, AKT serine/threonine kinase 1; FOXO3, forkhead box O3; RHOA, ras homolog family member A.](cmar-10-907Fig9){#f9-cmar-10-907}

###### 

Frequency of studies estimating prognostic value of blood miRNA expression in colorectal cancer

  miR     n   Reference(s)                             miR      n   Reference(s)                             miR       n   Reference(s)
  ------- --- ---------------------------------------- -------- --- ---------------------------------------- --------- --- --------------------
  15b     1   [@b1-cmar-10-907]                        122      1   [@b16-cmar-10-907]                       221       1   [@b26-cmar-10-907]
  17-3p   1   [@b2-cmar-10-907]                        124-5p   1   [@b9-cmar-10-907]                        324-3p    1   [@b12-cmar-10-907]
  19a     1   [@b3-cmar-10-907]                        135      1   [@b17-cmar-10-907]                       345       1   [@b12-cmar-10-907]
  21      4   [@b4-cmar-10-907]--[@b7-cmar-10-907]     139-5p   1   [@b18-cmar-10-907]                       372       1   [@b27-cmar-10-907]
  23b     1   [@b8-cmar-10-907]                        141      2   [@b14-cmar-10-907], [@b19-cmar-10-907]   628-5p    1   [@b12-cmar-10-907]
  26a     1   [@b9-cmar-10-907]                        143      1   [@b12-cmar-10-907]                       885-5p    1   [@b28-cmar-10-907]
  29a     1   [@b10-cmar-10-907]                       155      1   [@b20-cmar-10-907]                       886-3p    1   [@b12-cmar-10-907]
  29b     1   [@b11-cmar-10-907]                       183      1   [@b21-cmar-10-907]                       1290      1   [@b29-cmar-10-907]
  34a\*   1   [@b12-cmar-10-907]                       194      1   [@b11-cmar-10-907]                       4772-3p   1   [@b30-cmar-10-907]
  92a     2   [@b10-cmar-10-907], [@b13-cmar-10-907]   196b     1   [@b22-cmar-10-907]                       6826      1   [@b17-cmar-10-907]
  96      1   [@b14-cmar-10-907]                       200b     2   [@b14-cmar-10-907], [@b16-cmar-10-907]   6875      1   [@b17-cmar-10-907]
  103     1   [@b15-cmar-10-907]                       200c     1   [@b23-cmar-10-907]                                     
  106a    1   [@b2-cmar-10-907]                        203      2   [@b24-cmar-10-907], [@b25-cmar-10-907]                 

**Note:** Highlighted studies were included in the present meta-analysis.

###### 

Frequency of studies estimating prognostic value of tissue-miRNA expression in colorectal cancer

  miR        n    Reference(s)                                                 miR       n   Reference(s)                                                                                            miR       n   Reference(s)                                                                                            miR       n   Reference(s)                                                                        miR      n   Reference(s)
  ---------- ---- ------------------------------------------------------------ --------- --- ------------------------------------------------------------------------------------------------------- --------- --- ------------------------------------------------------------------------------------------------------- --------- --- ----------------------------------------------------------------------------------- -------- --- ---------------------------------------------------------------
  let7a-5p   1    [@b31-cmar-10-907]                                           34a-5p    1   [@b99-cmar-10-907]                                                                                      143       6   [@b59-cmar-10-907], [@b112-cmar-10-907], [@b150-cmar-10-907]--[@b153-cmar-10-907]                       211       1   [@b197-cmar-10-907]                                                                 487b     1   [@b233-cmar-10-907]
  let7a-2    1    [@b32-cmar-10-907]                                           34a       1   [@b100-cmar-10-907]                                                                                     144       1   [@b154-cmar-10-907]                                                                                     212       1   [@b198-cmar-10-907]                                                                 490-3p   1   [@b234-cmar-10-907]
  let7a      1    [@b33-cmar-10-907]                                           92a       3   [@b64-cmar-10-907], [@b101-cmar-10-907], [@b102-cmar-10-907]                                            145       5   [@b33-cmar-10-907], [@b64-cmar-10-907], [@b150-cmar-10-907], [@b155-cmar-10-907], [@b156-cmar-10-907]   214       1   [@b199-cmar-10-907]                                                                 491-5p   1   [@b205-cmar-10-907]
  let7b      1    [@b34-cmar-10-907]                                           93        2   [@b34-cmar-10-907], [@b103-cmar-10-907]                                                                 148a\*    1   [@b157-cmar-10-907]                                                                                     215       4   [@b58-cmar-10-907], [@b155-cmar-10-907], [@b179-cmar-10-907], [@b200-cmar-10-907]   494      2   [@b34-cmar-10-907], [@b235-cmar-10-907]
  let7c      1    [@b35-cmar-10-907]                                           96-5p     1   [@b104-cmar-10-907]                                                                                     148a      3   [@b81-cmar-10-907], [@b158-cmar-10-907], [@b159-cmar-10-907]                                            217       2   [@b201-cmar-10-907], [@b202-cmar-10-907]                                            498      1   [@b215-cmar-10-907]
  let7e      1    [@b18-cmar-10-907]                                           96        1   [@b105-cmar-10-907]                                                                                     149       2   [@b160-cmar-10-907], [@b161-cmar-10-907]                                                                218       2   [@b203-cmar-10-907], [@b204-cmar-10-907]                                            503      3   [@b227-cmar-10-907], [@b236-cmar-10-907], [@b237-cmar-10-907]
  let7g\*    1    [@b36-cmar-10-907]                                           99a-3p    1   [@b36-cmar-10-907]                                                                                      150       1   [@b162-cmar-10-907]                                                                                     221-3p    1   [@b205-cmar-10-907]                                                                 505\*    1   [@b36-cmar-10-907]
  let7g      1    [@b37-cmar-10-907]                                           99a       2   [@b35-cmar-10-907], [@b106-cmar-10-907]                                                                 153       1   [@b163-cmar-10-907]                                                                                     221\*     1   [@b206-cmar-10-907]                                                                 505      1   [@b32-cmar-10-907]
  let7i      1    [@b28-cmar-10-907]                                           99b-5p    1   [@b107-cmar-10-907]                                                                                     154       1   [@b164-cmar-10-907]                                                                                     221       2   [@b28-cmar-10-907], [@b207-cmar-10-907]                                             506      2   [@b238-cmar-10-907], [@b239-cmar-10-907]
  7          3    [@b34-cmar-10-907], [@b39-cmar-10-907], [@b40-cmar-10-907]   100       2   [@b106-cmar-10-907], [@b108-cmar-10-907]                                                                155       1   [@b60-cmar-10-907]                                                                                      223       1   [@b208-cmar-10-907]                                                                 515-5p   1   [@b134-cmar-10-907]
  9          1    [@b41-cmar-10-907]                                           101       1   [@b64-cmar-10-907]                                                                                      181a-1    1   [@b32-cmar-10-907]                                                                                      224       5   [@b206-cmar-10-907], [@b209-cmar-10-907]--[@b212-cmar-10-907]                       517a     1   [@b240-cmar-10-907]
  10b        4    [@b28-cmar-10-907], [@b42-cmar-10-907]--[@b44-cmar-10-907]   103a      1   [@b58-cmar-10-907]                                                                                      181a      5   [@b18-cmar-10-907], [@b165-cmar-10-907]--[@b168-cmar-10-907]                                            229-5p    1   [@b36-cmar-10-907]                                                                  542-3p   2   [@b241-cmar-10-907], [@b242-cmar-10-907]
  15a-5p     1    [@b45-cmar-10-907]                                           103-1     1   [@b81-cmar-10-907]                                                                                      181b      2   [@b18-cmar-10-907], [@b169-cmar-10-907]                                                                 296       1   [@b213-cmar-10-907]                                                                 556      1   [@b67-cmar-10-907]
  15a        1    [@b46-cmar-10-907]                                           103       1   [@b109-cmar-10-907]                                                                                     181 c     1   [@b170-cmar-10-907]                                                                                     320a      1   [@b28-cmar-10-907]                                                                  570      1   [@b157-cmar-10-907]
  16         3    [@b46-cmar-10-907]--[@b48-cmar-10-907]                       106a-5p   1   [@b110-cmar-10-907]                                                                                     182       3   [@b171-cmar-10-907]--[@b173-cmar-10-907]                                                                320e      1   [@b214-cmar-10-907]                                                                 573      1   [@b134-cmar-10-907]
  17-5p      3    [@b49-cmar-10-907]--[@b51-cmar-10-907]                       106a      7   [@b49-cmar-10-907], [@b64-cmar-10-907], [@b67-cmar-10-907], [@b111-cmar-10-907]--[@b114-cmar-10-907]    183       1   [@b174-cmar-10-907]                                                                                     320       1   [@b215-cmar-10-907]                                                                 579      1   [@b134-cmar-10-907]
  17         1    [@b52-cmar-10-907]                                           106b      3   [@b58-cmar-10-907], [@b115-cmar-10-907], [@b116-cmar-10-907]                                            185       1   [@b133-cmar-10-907]                                                                                     326       1   [@b216-cmar-10-907]                                                                 590-5p   2   [@b243-cmar-10-907], [@b244-cmar-10-907]
  18a        2    [@b53-cmar-10-907], [@b54-cmar-10-907]                       107       1   [@b36-cmar-10-907]                                                                                      187       2   [@b175-cmar-10-907], [@b176-cmar-10-907]                                                                328       1   [@b32-cmar-10-907]                                                                  592      2   [@b186-cmar-10-907], [@b245-cmar-10-907]
  19b        1    [@b38-cmar-10-907]                                           124-5 p   1   [@b9-cmar-10-907]                                                                                       188-3p    1   [@b177-cmar-10-907]                                                                                     335       1   [@b217-cmar-10-907]                                                                 610      1   [@b246-cmar-10-907]
  20a-5p     2    [@b55-cmar-10-907], [@b56-cmar-10-907]                       124       2   [@b117-cmar-10-907], [@b118-cmar-10-907]                                                                191       1   [@b178-cmar-10-907]                                                                                     337-5p    1   [@b36-cmar-10-907]                                                                  625-3p   1   [@b247-cmar-10-907]
  20a        2    [@b57-cmar-10-907], [@b58-cmar-10-907]                       125b      5   [@b33-cmar-10-907], [@b35-cmar-10-907], [@b106-cmar-10-907], [@b112-cmar-10-907], [@b119-cmar-10-907]   192       2   [@b179-cmar-10-907], [@b180-cmar-10-907]                                                                338-3p    1   [@b218-cmar-10-907]                                                                 625      1   [@b248-cmar-10-907]
  21         17   [@b5-cmar-10-907], [@b58-cmar-10-907]--[@b73-cmar-10-907]    126       6   [@b120-cmar-10-907]--[@b125-cmar-10-907]                                                                193a-5p   1   [@b181-cmar-10-907]                                                                                     340       1   [@b219-cmar-10-907]                                                                 630      1   [@b249-cmar-10-907]
  22         2    [@b74-cmar-10-907], [@b75-cmar-10-907]                       128       2   [@b126-cmar-10-907], [@b127-cmar-10-907]                                                                193b      1   [@b182-cmar-10-907]                                                                                     342-3p    1   [@b205-cmar-10-907]                                                                 638      1   [@b250-cmar-10-907]
  23b        2    [@b76-cmar-10-907], [@b77-cmar-10-907]                       130a      1   [@b81-cmar-10-907]                                                                                      194       3   [@b38-cmar-10-907], [@b183-cmar-10-907], [@b184-cmar-10-907]                                            361-5p    1   [@b220-cmar-10-907]                                                                 652      1   [@b32-cmar-10-907]
  24-3p      2    [@b78-cmar-10-907], [@b79-cmar-10-907]                       130b      1   [@b128-cmar-10-907]                                                                                     195-5p    1   [@b33-cmar-10-907]                                                                                      362-3p    1   [@b157-cmar-10-907]                                                                 664-3p   1   [@b186-cmar-10-907]
  25         1    [@b80-cmar-10-907]                                           132       2   [@b129-cmar-10-907], [@b130-cmar-10-907]                                                                195       2   [@b33-cmar-10-907], [@b34-cmar-10-907]                                                                  365-1     1   [@b76-cmar-10-907]                                                                  720      1   [@b251-cmar-10-907]
  26a-2      1    [@b81-cmar-10-907]                                           133a      2   [@b131-cmar-10-907], [@b132-cmar-10-907]                                                                196a      1   [@b185-cmar-10-907]                                                                                     365-2     1   [@b76-cmar-10-907]                                                                  802      1   [@b134-cmar-10-907]
  26b        1    [@b82-cmar-10-907]                                           133b      2   [@b133-cmar-10-907], [@b134-cmar-10-907]                                                                196b-5p   1   [@b186-cmar-10-907]                                                                                     365       1   [@b221-cmar-10-907]                                                                 875-5p   1   [@b252-cmar-10-907]
  29a        2    [@b83-cmar-10-907], [@b84-cmar-10-907]                       134       1   [@b135-cmar-10-907]                                                                                     196b      1   [@b185-cmar-10-907]                                                                                     370       1   [@b36-cmar-10-907]                                                                  885-5p   1   [@b28-cmar-10-907]
  29b        1    [@b85-cmar-10-907]                                           135b      3   [@b136-cmar-10-907]--[@b138-cmar-10-907]                                                                197       1   [@b32-cmar-10-907]                                                                                      372       1   [@b222-cmar-10-907]                                                                 889      1   [@b36-cmar-10-907]
  30a-5p     1    [@b86-cmar-10-907]                                           137       2   [@b139-cmar-10-907], [@b140-cmar-10-907]                                                                198       1   [@b187-cmar-10-907]                                                                                     376a      1   [@b223-cmar-10-907]                                                                 944      1   [@b157-cmar-10-907]
  30a        1    [@b87-cmar-10-907]                                           138-5p    2   [@b141-cmar-10-907], [@b142-cmar-10-907]                                                                199a-3p   1   [@b188-cmar-10-907]                                                                                     378a-3p   1   [@b224-cmar-10-907]                                                                 1260b    1   [@b253-cmar-10-907]
  30b        1    [@b88-cmar-10-907]                                           138       1   [@b143-cmar-10-907]                                                                                     199b      1   [@b189-cmar-10-907]                                                                                     378a-5p   1   [@b224-cmar-10-907]                                                                 1288     1   [@b254-cmar-10-907]
  30d        1    [@b89-cmar-10-907]                                           139-3p    1   [@b144-cmar-10-907]                                                                                     200a      3   [@b82-cmar-10-907], [@b149-cmar-10-907], [@b190-cmar-10-907]                                            378       1   [@b225-cmar-10-907]                                                                 1290     1   [@b29-cmar-10-907]
  31-3p      2    [@b90-cmar-10-907], [@b91-cmar-10-907]                       139-5p    2   [@b18-cmar-10-907], [@b145-cmar-10-907]                                                                 200c      3   [@b23-cmar-10-907], [@b149-cmar-10-907], [@b191-cmar-10-907]                                            422a      2   [@b141-cmar-10-907], [@b226-cmar-10-907]                                            1292     1   [@b227-cmar-10-907]
  31-5p      3    [@b91-cmar-10-907]--[@b93-cmar-10-907]                       139       1   [@b146-cmar-10-907]                                                                                     203       2   [@b24-cmar-10-907], [@b192-cmar-10-907]                                                                 424-3p    1   [@b227-cmar-10-907]                                                                 1297     1   [@b255-cmar-10-907]
  31         4    [@b64-cmar-10-907], [@b94-cmar-10-907]--[@b96-cmar-10-907]   140-5p    2   [@b147-cmar-10-907], [@b148-cmar-10-907]                                                                204-5p    2   [@b193-cmar-10-907], [@b194-cmar-10-907]                                                                429       5   [@b149-cmar-10-907], [@b228-cmar-10-907]--[@b231-cmar-10-907]                       1826     1   [@b256-cmar-10-907]
  32         2    [@b32-cmar-10-907], [@b97-cmar-10-907]                       141       2   [@b34-cmar-10-907], [@b149-cmar-10-907]                                                                 206       1   [@b195-cmar-10-907]                                                                                     450b-5p   1   [@b232-cmar-10-907]                                                                 4500     1   [@b257-cmar-10-907]
  33b        1    [@b98-cmar-10-907]                                           143-5p    1   [@b58-cmar-10-907]                                                                                      210       1   [@b196-cmar-10-907]                                                                                     455-5p    1   [@b186-cmar-10-907]                                                                 4775     1   [@b258-cmar-10-907]

**Note:** Highlighted studies were included in the present meta-analysis.

###### 

Characteristics of studies included on colorectal cancer

  miRNA   Study                                    Country/source    Design   Sample         Number    Stage       Cutoff    Method       Follow-up (months)   Result                                              HR (L/H)   HR (H/L)   95% CI
  ------- ---------------------------------------- ----------------- -------- -------------- --------- ----------- --------- ------------ -------------------- --------------------------------------------------- ---------- ---------- -------------
  21      Menéndez et al[@b4-cmar-10-907]          Spain             P        Serum          102       I--IV       1.00      qRT-PCR      36                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  0.50       0.25--1.02
                                                                                                                                                               DFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 0.51       0.25--1.06
  21      Toiyama et al[@b5-cmar-10-907]           Japan             R        Serum          188       I--IV       \<0.01    RT-qPCR      84                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  4.12       1.10--15.40
  21      Monzo et al[@b6-cmar-10-907]             Spain             R        Plasma         52        I--IV       Median    TaqMan       48                   DFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                2.32       0.80--6.71
  21      Tsukamoto et al[@b7-cmar-10-907]         Japan             R        Plasma         326       I--IV       Median    qRT-PCR      84                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  2.28       1.81--5.74
                                                                                             259                                                               DFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 2.34       1.87--4.60
  92a     Wang and Gu[@b10-cmar-10-907]            China             R        Serum          74        II--IV      \<0.06    RT-qPCR      35                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 1.17       0.70--1.97
  92a     Liu et al[@b13-cmar-10-907]              China             R        Serum          166       I--IV       \<0.01    RT-qPCR      53                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  4.36       1.64--11.57
  141     Cheng et al[@b19-cmar-10-907]            China, USA        R        Plasma         258       I--IV       Median    RT-qPCR      96                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  2.40       1.18--4.86
  141     Sun et al[@b14-cmar-10-907]              USA               R        Plasma         168       I--IV       Mean      RT-qPCR      96                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 2.58       1.58---4.21
  200b    Maierthaler et al[@b16-cmar-10-907]      Germany I         R        Plasma         308       I--IV       Median    RT-qPCR      \>72                 OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  0.77       0.57--1.05
                                                   Germany II                                219                                                               OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  1.21       0.98--1.50
  200b    Sun et al[@b14-cmar-10-907]              USA               R        Plasma         169       I--IV       Mean      RT-qPCR      96                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 2.46       1.57--3.85
  203     Hur et al[@b24-cmar-10-907]              Japan             R        Serum          186       I--IV       ROC       RT-qPCR      70                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  2.14       1.09--4.21
  203     Shi et al[@b25-cmar-10-907]              China             R        Serum          180       II--IV      Median    RT-qPCR      60                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 0.47       0.27--0.81
  21      Kulda et al[@b59-cmar-10-907]            Czech Republic    R        Frozen         46        I--IV       8.10      RT-qPCR      56                   DFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                1.80       0.05--65.37
  21      Shibuya et al[@b60-cmar-10-907]          Japan             R        Frozen         156       I--IV       Mean      TaqMan       84                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  1.95       1.05--4.48
                                                                                             116                                                               DFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 2.53       1.15--5.59
  21      Nielsen et al[@b61-cmar-10-907]          Denmark I         R        FFPE           129       II          65%       ISH          \>60                 OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 1.17       1.02--1.34
                                                                                                                                                               DFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 1.29       1.06--1.56
                                                   Denmark II                                67                                                                OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 0.97       0.83--1.13
                                                                                                                                                               DFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 0.85       0.73--1.01
  21      Faltejskova et al[@b62-cmar-10-907]      Czech Republic    R        Tissue         44        I--IV       Median    RT-qPCR      86                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 2.72       0.63--11.83
  21      Kjaer-Frifeldt et al[@b63-cmar-10-907]   Denmark           P        FFPE           520       II          Mean      ISH          84                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  1.08       0.97--1.22
                                                                                                                                                               RF-CSS[a](#tfn3-cmar-10-907){ref-type="table-fn"}              1.41       1.19--1.67
  21      Schee et al[@b64-cmar-10-907]            Norway            P        Frozen         193       I--III      Median    qRT-PCR      \>60                 MFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                1.17       0.59--2.32
  21      Chen et al[@b65-cmar-10-907]             China             R        Tissue         195       I--IV       Mean      RT-qPCR      \>100                OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  2.56       1.43--4.57
  21      Toiyama et al[@b5-cmar-10-907]           Japan             R        FFPE           166       I--IV       3.70      RT-qPCR      84                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  0.59       0.21--1.63
  21      Oue et al[@b66-cmar-10-907]              Japan             R        FFPE           87        II--III     None      qRT-PCR      60                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  3.13       1.20--8.17
                                                   Germany                                   145       II                                                      OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  2.65       1.06--6.66
  21      Bullock et al[@b67-cmar-10-907]          UK                P        Frozen, FFPE   50        II          Mean      qRT-PCR      96                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 2.47       1.19--5.55
                                                                                                                                                               DFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                2.68       1.21--5.93
  21      Fukushima et al[@b68-cmar-10-907]        Japan             R        Frozen         306       I--IV       Mean      RT-qPCR      90                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  2.88       1.70--5.08
                                                                                             244                                                               DFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 2.94       1.68--5.36
  21      Kang et al[@b69-cmar-10-907]             South Korea       R        FFPE           277       IIA--IIIC   Median    ISH          80                   RFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 2.24       1.25--4.02
  21      Caritg et al[@b58-cmar-10-907]           Spain             R        Frozen         69        II          2.04      TaqMan       \>140                DFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                1.33       0.14--12.47
  21      Feiersinger et al[@b70-cmar-10-907]      Germany           R        FFPE           29        I--IV       Median    qRT-PCR      205.15               OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 1.45       0.39--5.43
                                                                                                                                                               DFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                1.76       0.75--4.11
  21      Iseki et al[@b71-cmar-10-907]            Japan             R        FFPE           32        None        8.10      qRT-PCR      63.2                 OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  2.52       0.65--8.34
                                                                                                                                                               PFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 4.93       1.08--20.81
  21      Lee et al[@b72-cmar-10-907]              South Korea       R        FFPE           170       I--IV       Median    ISH          105                  OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 0.93       0.54--1.60
  21      Mima et al[@b73-cmar-10-907]             USA I             P        FFPE           190/192   I--IV       25%       RT-qPCR      207.6                OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  0.99       0.75--1.31
                                                                                                                                                               CSS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 0.88       0.58--1.31
                                                   USA II                                    192/192               50%                                         OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  1.03       0.78--1.35
                                                                                                                                                               CSS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 1.10       0.75--1.60
                                                   USA III                                   191/192               75%                                         OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  1.40       1.07--1.84
                                                                                                                                                               CSS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 1.42       0.98--2.04
  106a    Díaz et al[@b49-cmar-10-907]             Spain             R        Frozen         110       I--IV       Median    RT-qPCR      99                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  0.53       0.26--1.08
                                                                                                                                                               DFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 0.36       0.17--0.78
  106a    Feng et al[@b111-cmar-10-907]            China             R        Frozen         28        MB--NIB     Median    qRT-PCR      60                   MFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                3.63       0.56--23.68
  106a    Schee et al[@b64-cmar-10-907]            Norway            P        Frozen         193       I--III      Median    qRT-PCR      \>60                 MFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                0.81       0.41--1.59
  106a    Ak et al[@b112-cmar-10-907]              Turkey            R        FFPE           40        I--IV       None      qRT-PCR      \>200                OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 0.94       0.35--2.56
  106a    Bullock et al[@b67-cmar-10-907]          UK                P        Frozen, FFPE   50        II          Mean      qRT-PCR      96                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 2.25       1.00--5.04
                                                                                                                                                               DFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                2.91       1.32--6.42
  106a    Hao et al[@b113-cmar-10-907]             China             R        Tissue         138       I--IV       66%       RT-qPCR      \>60                 OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  1.87       1.13--3.09
                                                                                                                                                               DFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 1.22       0.70--2.12
  106a    Hao et al[@b114-cmar-10-907]             China             R        FFPE           65        I--IV       Median    qRT-PCR      \>60                 OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 2.00       0.51--7.85
  125b    Nishida et al[@b119-cmar-10-907]         Japan             R        Frozen         89        None        Median    RT-qPCR      \>96                 OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 2.42       0.99--5.91
  125b    Ak et al[@b112-cmar-10-907]              Turkey            R        FFPE           40        I--IV       None      qRT-PCR      \>200                OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 0.90       0.32--2.56
  125b    Cappuzzo et al[@b35-cmar-10-907]         Italy             R        FFPE           183       None        None      None         48                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  0.58       0.32--1.05
  125b    Rokavec et al[@b106-cmar-10-907]         TCGA              R        Tissue         438       I--IV       None      Downloaded   \>133                OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 1.88       1.36--2.60
  125b    Sun et al[@b33-cmar-10-907]              TCGA              R        Tissue         107       I--IV       Median    Downloaded   141.1                OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 2.29       1.33--3.92
  126     Hansen et al[@b120-cmar-10-907]          Denmark           R        FFPE           89        None        Median    ISH          58                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}      1.93                  1.13--3.29
                                                                                             83                                                                PFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}     2.69                  1.42--5.08
  126     Hansen et al[@b121-cmar-10-907]          Sweden, Denmark   P        FFPE           89        None        Median    qRT-PCR      \>30                 PFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}      2.04                  1.19--3.45
  126     Hansen et al[@b122-cmar-10-907]          DCCG              P        FFPE           560       II          Median    qRT-PCR      84                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}       1.32                  1.00--1.72
                                                                                                                                                               RF-CSS[a](#tfn3-cmar-10-907){ref-type="table-fn"}   1.04                  0.71--1.52
  126     Liu et al[@b123-cmar-10-907]             China             R        Frozen         92        I--IV       None      qRT-PCR      92                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}      2.65                  1.00--6.98
  126     Ebrahimi et al[@b124-cmar-10-907]        Australia         R        FFPE           132       I--IV       \<l/\>2   qRT-PCR      \>100                OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}      1.81                  0.82--4.00
  126     Yuan et al[@b125-cmar-10-907]            China             R        Tissue         75        I--IV       0/\>0     ISH          68                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}      2.35                  0.91--6.06
  143     Kulda et al[@b59-cmar-10-907]            Czech Republic    R        Frozen         46        I--IV       11.40     RT-qPCR      56                   DFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}     0.45                  0.07--2.78
  143     Drebber et al[@b150-cmar-10-907]         Germany           R        FFPE           40        I--IV       1.00      RT-qPCR      76.8                 OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}      1.52                  0.32--7.22
  143     Pichler et al[@b151-cmar-10-907]         Austria           R        FFPE           77        II--IV      None      qRT-PCR      \>125                CSS[a](#tfn3-cmar-10-907){ref-type="table-fn"}      1.86                  1.06--3.25
                                                                                             52                                                                PFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}     1.55                  0.91--2.66
  143     Guo et al[@b152-cmar-10-907]             China             R        Tissue         79        I--IV       Median    qRT-PCR      122                  OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}      1.45                  0.69--3.07
  143     Ak et al[@b112-cmar-10-907]              Turkey            R        FFPE           40        I--IV       1.76      qRT-PCR      \>200                OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}      2.69                  0.80--9.08
  143     Simmer et al[@b153-cmar-10-907]          DCCG              P        FFPE           55        I--IV       Median    TaqMan       42                   PFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}      0.45                  0.24--0.85
  145     Drebber et al[@b150-cmar-10-907]         Germany           R        FFPE           40        I--IV       0.10      RT-qPCR      76.8                 OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}      1.95                  0.43--8.79
  145     Schee et al[@b64-cmar-10-907]            Norway            P        Frozen         193       I--III      Median    qRT-PCR      \>60                 MFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}     0.61                  0.30--1.22
  145     Pecqueux et al[@b155-cmar-10-907]        Germany           R        Frozen         47        None        Median    RT-qPCR      \>60                 OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}      3.73                  1.45--9.55
  145     Zhou et al[@b156-cmar-10-907]            China             R        Frozen         60        I--IV       Median    qRT-PCR      80                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}      2.57                  1.12--5.90
                                                                                                                                                               DFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}     2.58                  1.12--5.94
  145     Sun et al[@b33-cmar-10-907]              TCGA              R        Tissue         107       I--IV       Median    Downloaded   \>144                OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}      0.52                  0.30--0.77
  181a    Nishimura et al[@b165-cmar-10-907]       Japan             R        Frozen         162       I--IV       Median    qRT-PCR      \>144                OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 2.00       1.05--3.80
                                                                                                                                                               DFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                2.26       1.10--4.61
  181a    Ji et al[@b166-cmar-10-907]              China I           R        Tissue         137       I--IV       Median    RT-qPCR      100                  OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  1.87       1.08--3.25
                                                   China II                   FFPE           294                   1.00      ISH                               OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  1.38       1.11--1.72
  181a    Pichler et al[@b167-cmar-10-907]         Austria           R        FFPE           80        II--IV      None      qRT-PCR      \>125                CSS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 0.63       0.37--1.21
                                                                                             54                                                                PFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                0.57       0.36--0.91
  181a    Li et al[@b168-cmar-10-907]              China             R        Frozen         72        I--IV       None      RT-qPCR      \>60                 OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 2.06       1.00--4.23
  181a    Miyoshi et al[@b18-cmar-10-907]          TCGA              R        Tissue         93        II--III     None      Downloaded   135                  RFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                2.85       1.24--6.55
  224     Liao et al[@b209-cmar-10-907]            China             R        Frozen         110       I--IV       Median    qRT-PCR      87                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 1.82       0.88--3.79
  224     Yuan et al[@b206-cmar-10-907]            China             R        Tissue         108       I--III      None      qRT-PCR      60                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  0.27       0.14--0.51
                                                                                             54                                                                DFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 0.07       0.02--0.25
  224     Zhang et al[@b210-cmar-10-907]           China             R        Frozen         108       I--II       25.72     qRT-PCR      62.5                 DFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                1.87       0.79--4.41
  224     Adamopoulos et al[@b211-cmar-10-907]     Greece            R        Frozen         104       I--IV       56%       qRT-PCR      120                  OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  4.41       1.72--11.34
                                                                                             91                                                                DFS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                 4.61       1.41--15.09
  224     Ling et al[@b212-cmar-10-907]            TCGA              R        Tissue         143       I--IV       None      Downloaded   72                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  2.88       0.97--8.56
                                                   Italy I                                   54                              qRT-PCR      115                  OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  2.77       0.95--8.11
                                                   Italy II                                  68                              qRT-PCR      115                  OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  4.14       0.96--17.76
                                                   Romania                                   38                              qRT-PCR      70                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  1.76       0.36--8.64
                                                   Austria                                   74                              qRT-PCR      130                  OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  2.36       1.32--4.21
                                                   UK                                        41                              qRT-PCR      60                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 4.92       1.31--18.46
                                                                                                                                                               MFS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                6.51       1.97--21.51
  429     Li et al[@b228-cmar-10-907]              China             R        Frozen         107       I--III      Median    qRT-PCR      82                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 2.09       0.84--5.17
  429     Diaz et al[@b149-cmar-10-907]            Spain             R        Frozen         127       I--III      None      TaqMan       113                  OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 0.35       0.16--0.77
  429     Sun et al[@b229-cmar-10-907]             China             R        Frozen         84        I--IV       None      qRT-PCR      96                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 0.29       0.16--0.55
  429     Dong et al[@b230-cmar-10-907]            China             R        Frozen         78        I--IV       Median    qRT-PCR      60                   OS[b](#tfn3a-cmar-10-907){ref-type="table-fn"}                 2.66       1.25--5.68
  429     Han et al[@b231-cmar-10-907]             China             R        Frozen         71        I--IV       Median    qRT-PCR      60                   OS[a](#tfn3-cmar-10-907){ref-type="table-fn"}                  1.85       1.02--3.33

**Notes:**

multiple-covariate analysis;

Univariate analysis;

**Abbreviations:** L/H, low versus high miRNA expression; H/L, high versus low miRNA expression; P, prospective; qRT-PCR, quantitative real-time polymerase chain reaction; OS, overall survival; DFS, disease-free survival; R, retrospective; RT-qPCR, reverse transcription qRT-PCR; RF-CSS, recurrence-free cause-specific survival; ROC, receiver-operating characteristic; FFPE, formalin-fixed, paraffin-embedded; ISH, in situ hybridization; MFS, metastasis-free survival; RFS, recurrence-free survival; PFS, progression-free survival; CSS, cause-specific survival; TCGA, the Cancer Genome Atlas; DCCG, Dutch Colorectal Cancer Group.

###### 

Meta-analysis results for miRNA expression in colorectal cancer

  miRNA          Survival analysis                                         Articles   Studies included                HR     95% CI       Figure   *P*-value   Heterogeneity (Higgins's *I*^2^)   Patients, n
  -------------- --------------------------------------------------------- ---------- ------------------------------- ------ ------------ -------- ----------- ---------------------------------- -------------
  High miR21     OS                                                        3          4, 5, 7                         1.56   0.47--5.23   2        0.47        85.2%, *P*\<0.01                   616
  High miR21     DFS                                                       3          4, 6, 7                         1.39   0.49--3.96   2        0.53        84.4%, *P*\<0.01                   480
  High miR92a    OS                                                        2          10, 13                          2.11   0.59--7.61   2        0.25        81.6%, *P*=0.02                    240
  High miR141    OS                                                        2          14, 19                          2.52   1.68--3.77   2        \<0.01      0.0%, *P*=0.87                     426
  High miR200b   OS                                                        2          14, 16                          1.28   0.75--2.19   2        0.36        88.8%, *P*\<0.01                   696
  High miR203    OS                                                        2          24, 25                          0.99   0.22--4.37   2        0.99        91.4%, *P*\<0.01                   366
  High miR21     OS                                                        13         5, 60--68, 70--73               1.31   1.12--1.53   3A       \<0.01      65.3%, *P*\<0.01                   2,861
  High miR21     OS[a](#tfn5-cmar-10-907){ref-type="table-fn"}             8          5, 60, 63, 65, 66, 68, 71, 73   1.47   1.16--1.87   3A       \<0.01      71.7%, *P*\<0.01                   2,372
  High miR21     DFS                                                       7          58--61, 67, 68, 70              1.64   1.11--2.41   3D       0.01        79.2%, *P*\<0.01                   554
  High miR21     RFS/CSS/MFS/PFS                                           5          63, 64, 69, 71, 73              1.33   1.06--1.67   3D       0.01        48.6%, *P*=0.07                    1,787
  High miR21     OS, adjusted[b](#tfn6-cmar-10-907){ref-type="table-fn"}                                              1.13   0.96--1.34   4B       0.15        71.6%, *P*\<0.01                   
  High miR106a   OS                                                        5          49, 67, 112--114                1.31   0.72--2.36   5        0.38        62.2%, *P*=0.03                    403
  High miR106a   DFS/MFS                                                   5          49, 64, 67, 11, 113             1.14   0.55--2.36   5        0.72        75.8%, *P*\<0.01                   519
  High miR125b   OS                                                        5          33, 35, 106, 112, 119           1.43   0.83--2.47   5        0.19        74.6%, *P*\<0.01                   857
  Low miR126     OS                                                        5          120, 122--125                   1.55   1.24--1.93   6        \<0.01      1.2%, *P*=0.40                     948
  Low miR126     PFS/RFS/CSS                                               3          120--122                        1.72   0.95--3.10   6        0.07        75.2%, *P*=0.02                    732
  Low miR143     DFS/CSS/PFS                                               3          59, 151, 153                    1.00   0.47--2.13   6        1.00        77.7%, *P*\<0.01                   230
  Low miR143     OS                                                        3          112, 150, 152                   1.69   0.94--3.04   6        0.08        0.0%, *P*=0.69                     159
  Low miR145     OS                                                        4          33, 150, 155, 156               1.68   0.55--5.12   7        0.36        85.4%, *P*\<0.01                   254
  Low miR145     MFS/DFS                                                   2          64, 156                         1.23   0.30--5.06   7        0.77        85.1%, *P*\<0.01                   253
  High miR181a   OS                                                        3          165, 166, 168                   1.52   1.26--1.83   7        \<0.01      0.0%, *P*=0.45                     665
  High miR181a   DFS/CSS/PFS/RFS                                           3          18, 165, 67                     1.17   0.53--2.59   7        0.69        84.0%, *P*\<0.01                   309
  High miR224    OS                                                        4          206, 209, 211, 212              2.12   1.04--4.34   8        0.04        80.9%, *P*\<0.01                   740
  High miR224    DFS/MFS                                                   4          206, 210--212                   1.43   0.23--8.77   8        0.70        90.6%, *P*\<0.01                   294
  High miR429    OS                                                        5          146, 228--231                   1.00   0.39--2.58   8        1.00        88.7%, *P*\<0.01                   467

**Notes:**

Multiple-covariate analysis;

adjusted with trim-and-fill method.

**Abbreviations:** OS, overall survival; DFS, disease-free survival; RFS, recurrence-free survival; CSS, cause-specific survival; MFS, metastasis-free survival; PFS, progression-free survival.
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